Bioluminescence Enhanced Enzyme Immunoassay. New Ultrasensitive Detection Systems for Enzyme Immunoassays, II. by Geiger, R. & Miska, W.
Geiger and Miska: Bioluminescence enhanced enzyme immunoassay 31
J. Clin. Chem. Clin. Biochem.
Vol. 25, 1987, pp. 31-38
© 1987 Walter de Gruyter & Co.
Berlin - New York
Bioluminescence Enhanced Enzyme Immunoassay
New Ultrasensitive Detection Systems for Enzyme Immunoassays, II.1)
By R. Geiger and W. Miska
Abteilung für Klinische Chemie und Klinische Biochemie in der Chirurgischen Klinik Innenstadt der Universität
München, München, FRG
(Received April 21/August 11, 1986)
Summary: Ultrasensitive bioluminescence immunoassays for the determination of peptides and proteins
(illustrated with human urinary kallikrein, bradykinin and the determination of human urinary kallikrein
antibody titers) have been developed. The usable ranges of the Standard curves are from 5 pg to 5000 pg per
liter. The relative intra-assay coefficients of Variation of the tests were between 2 and 6%, and the inter-
assay coefficients of Variation between 4 and 12%.
Introduction
Despite widespread application of radioimmunoas-
says, non-isotopic immunoassays have been devel-
oped during the past decade (l, 2). In particular,
enzyme immunoassays (3 — 8) have proved to be a
useful alternative to radioimmunoassays. Although
both radio- and enzyme immunoassays have similar
sensitivities for antigen determination, enzyme immu-
noassay häs several advantages (9) and allows meas-
urement of the signal in generally available spectro-
photometers.
More recently, highly sensitive bipluminescent and
luminescent detection Systems have become available
for the determination of ATP and many different
analytes (10—13). Bioluminescence is a natufal phe^
nomenon found in many lower forms of life (14).
Naturally ocurring bioluminescent Systems differ with
regard to the structure and function of enzymes and
cofactors, äs well äs in the mechanism of the light
emitting reactions (11—21).
In this communication we describe and demonstrate
highly sensitive enzyme immunoassays in which bio
luminescence is used äs the detection System. The
I.:tbisj. 25, 23-30(1987).
principle of these bioluminescence enhanced immu-
noassays is äs follows: an antibody enzyme or antigen
enzyme conjugate becomes bound in the enzyme im-
munoassay, then enzymatically releases ZMuciferin
from luciferin derivatives. The D-luciferin is quanti-
fied in a luminometric assay.
Materials aiid Methods
Sephadex G-15, G-150 and N-succinimidyl 3-(2-pyridyldithio)
propionate (SPDP®) were products of Pharmacia Fine Chemi-
cals, Uppsala, Sweden.
D-luciferin (Photinus pyralis), carboxylic esterase, carboxypep-
tidases A and B, arylsulphatase, alkaline phosphatase, Tween
20, and bovine semm albumin were purchased from Sigma
Chemicals, Deisenhofen, FRG.
Glutardialdehyde was purchased from E. Merck, Darmstadt,
FRG.
Luciferase (Photinus pyralis; specific activity 8 mU/mg) was a
product of Boehringer, Mannheim, FRG.
Bradykinin was a product of Novabiochem AG, Läufelfingen,
Switzerland.
Human urinary kallikrein was isolated äs described by Geiger
et al. (22).
Antibodies against human urinary kallikrein and bradykinin
were raised in rabbits and in goats äs already described (23).
IgG fractions were isolated according to Steinbuch & Audran
(25).
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Bradykinin antibodies, purified by immunoaffmity, were pre-
pared s described in 1. c. (26).
Goat anti-rabbit immunoglobulins, purified by immunoaffi-
nity, were purchased from M es/Yeda Ltd., Rehovot, Israel.
Microtiter plates were purchased from Dynatech, Denkendorf,
FRG.
D-luciferin methyl ester, ZMuciferyl-L-phenylalanine, ZMuci-
feryl-L-Na-arginine, ZMuciferin-O-sulphate and ZMuciferin-O-
phosphate were synthesized s described (9).
Enzyme2) conjugates
Bradykinin, human urinary kallikrein and immunoglobulin G
were conjugated with carboxylic esterase, carboxypeptidases A
and B, arylsuiphatase and alkaline phosphatase. Coupling to
carboxylic esterase was performed with glutardialdehyde and/
or N-succinimidyl 3-(2-pyridyldithio) proprionate (27), and to
carboxypeptidases A and B, arylsuiphatase and alkaline phos-
phatase with SPDP® s described by Carhson et al. (28). All
conjugates synthesized were purified by gel filtration on Sepha-
dex G-15 (bradykinin) or G-150 (human urinary kallikrein and
IgG) equilibrated with 0.1 mol/1 phosphate buffer, pH 7.5,
containing 0.25 mol/1 NaCl, at 4°C. The concentrations of
enzyme conjugates in the resulting reagent Solutions were deter-
mined by measuring enzyme activities by conventional methpds
s described (9). Aliquots of the enzyme conjugates were stored
at — 30 °C until use.
Luminometric assay
Luciferase activity was measured in a luminometer (Biolumat,
Fa. Berthold Typ 9500 T, Wildbad, FRG) s follows (10): 0.4
ml incubation buffer (30 mmol/1 HEPES, 6.6 mmol/1 MgCl2,
0.66 mmol/1 EDTA, 0.1 mmol/1 dithiothreitol, 5 mmol/1 ATP,
pH 7.75 containing l μg luciferase) was preincubated in a
cuvette at 25 °C for 5 min in the luminometer. Thereafter 0.1
ml luciferin solution or incubation Solutions of the immunoas-
say were added and the integrated light impulses were moni-
tored for 10 s.
Kinetics of luciferin liberation from luciferin deriva-
tives
Microtiter plates were coated with rabbit IgG (10 mg/1 buffer
A) overnight at 4 °C. After washing with buffer B (5 times),
0.2 ml of goat anti-rabbit IgG enzyme conjugates were added
(for concentrations of enzyme conjugate in test, see table 1)
and incubated at 37 °C for 5 h. Then the plates were washed
with buffer B (5 times), 0.2 ml Substrate solution was added
and luciferin release was measured after the time indicated.
Tab. 1. Conjugates of the bioluminescence enhanced enzyme
immunoassay.
Conjugate Conjugate
activity*)
in the assay
(kU/1)
Bradykinin
carboxylic esterase
carboxypeptid se A
carboxypeptidase B
arylsuiphatase
alkaline phosphatase
Human urinary kallikrein
carboxylic esterase
c fboxypeptidase A
carboxypeptidase B
Anti-human urinary kallikrein
carboxylic esterase
carboxypeptidase A
carboxypeptidase B
alkaline phosphatase
Immunoglobulin G
carboxylic esterase
carboxypeptidase A
carboxypeptidase B
arylsuiphatase
alkaline phosphatase
5.8
29
35
1.7
0.12
7,2
21
29
0.37
25
31
0.22
0.62
6.5
3.5
1.5
0.11
*) enzymatic activity was measured s described in Material
and Methods using chromogenic Substrates.
Tab. 2. Scheme of the detection Systems of the bioluminescenee
enhanced enzyme immunoassay.
Volume
(ml)
Addition of D-luciferin derivative
solution to the microtiter plate wells
Transfer to the luminometer
0.20
60 min at 37 °C*>
0.10
light impulses
were read for 10s
*) in the alkaline phosphatase-based detection System, the sys-
tem was incubated for only 30 min.
Detection Systems for bioluminescence enzyme im-
munoassay
Enzyme activities of the enzyme conjugates adsorbed onto
microtiter plates in the assay were determined s summarized
in table 2. The assays were performed s follows: 0.2 ml D-
luciferin derivative solution was added to the microtiter plate
wells and incubated for 60 min at 37 °C (alkaline phosphatase-
2) Enzymes
«Alkaline phosphatase (EC 3.1.3.1),
arylsuiphatase (EC 3.1.6.1),
carboxylic esterase (EC 3.1.1.1),
carboxypeptidase A (EC 3.4.17.1)
carboxypeptidase B (EC 3.4.17.2) and
human urinary kallikrein (EC 3.4.21.35).
based detection Systems were incubated only for 30 min at
37 °C). Thereafter, 0.1 ml of the incubation mixture was trans^
fered to the luminometer and light impulses were monitored
for 10 s.
The luciferin derivative Solutions used contained the following
concentrations:
2 μιηοΙ/1 ZMuciferin methyl ester in 0.05 mol/1 Tris/HCl, pH
/.D;
10 μπιοΙ/1 /Muciferyl-L-phenylalanine in 0.05 mol/1 Tris/HCl,
3 g/l LiCl, pH 7.5; .
10 μήίοΐ/ΐ ZMudferyl-L-Na-argimne in 0.05 Tris/HCl, 0.2 mol/1
NaCl, pH 7.8;.
10 μϊηοΐ/ΐ /M ciferin- -sulphate in 10 mmol/1 sodium acetate,
pH 5.0 and
10βμιηο1/1 /)-luciferin- -phosphate in 10 mmol/1 diethanol-
amine, 0.5 mmol/l MgCl2, pH 9.8.
r
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Enzyme immunoassay conditions (fig. 1)
Buffer A: 15 mmoi/1 Na2CO3, 0.35 mol/1 NaHCO3, 0.2 g/l
NaN3, pH 9.6
Buffer B: 10 mmol/1 KH2PO4,15 mmol/1 NaCl, 0.05 g/l, Tween
20, pH 7.4
Buffer C: 1.5 mmol/1 KH2PO4 x H2O, 0.14 mol/1 NaCl, 0.5
g/l Tween 20, 2 mg/ml bovine serum albumin, pH
7.4
Competitive human urinary kallikrein enzyme immunoassay
Microtiter plates were coated with rabbit anti-human urinary
kallikrein IgG (10 mg/1) in buffer A; 0.2 ml) at 4 °C overnight.
Thereafter the plates were washed (5 times) with buffer B. Then
0.15 ml of human urinary kallikrein Standard or lest sample
and 0.05 ml of a human urinary kallikrein enzyme conjugate
solution (see above) were added, and the mixture was incubated
for 24 h at 4 °C. The plates were washed with buffer B, then
0.2 ml of the corresponding D-luciferin derivative solution was
added and detected äs described in "detection Systems".
Human urinary kallikrein immune enzymometric assay
Microtiter plates were coated with human urinary kallikrein
(10 mg/1 buffer A; 0.2 ml per well) overnight at 4 °C. In parallel
to, but separately from the coating procedure, 0.5 ml anti-
human urinary källikrein IgG solution (0.1 g/l specific anti-
bodies in buffer C) and 0.5 ml human urinary kallikrein sol-
ution (0.01 — 10 ng/1 buffer C) were incubated in capped poly-
propylene vials overnight at 4 °C. The microtiter plates were
washed with buffer B (5 times). Thereafter, 0.2 ml of each
incubation mixture was transferred from the polypropylene
vials to the corresponding microtiter plate wells and incubated
at 37 °C for 5 h. After washing the plates (5 times), 0.2 ml of
a goat anti-rabbit IgG enzyme conjugate solution in buffer C
was added to each well and the plates were incubated again
for 24h at 4°C. The plates were washed with buffer B (5
times), then the corresponding /Muciferin derivative solution
(0.2 ml) was added to the wells. Bound IgG conjugates were
detected äs described in Materials and Methods.
Human urinary kallikrein Sandwich antigen assay
Microtiter plates were coated with goat anti-human urinary
kallikrein-IgG (10 mg/1 buffer A; 0.2 ml per well) at 4°C
overnight. The plates were then washed (5 times) in buffer B.
Human urinary kallikrein Standard samples and test samples
were diluted with buffer C. Of these samples 0.2 ml was added
to the wells and the plates were incubated at 4 °C for 24 h.
After incubation, the plates were washed (5 times) with buffer
B, 0.2 ml of rabbit anti-human urinary kallikrein-IgG enzyme
conjugate solution was added to each well, the plates were
washed (5 times), then 0.2 ml of the corresponding ZMuciferin
derivative Substrate solution (see detection Systems) was added
to the wells, and the human urinary kallikrein-bound IgG
conjugates were detected äs described in Materials and
Methods.
Competitive bradykinin enzyme immunoassay
Microtiter plates were coated overnight at 4 °C with immunose-
lected anti-bradykinin IgG solution (10 mg/1 in buffer A; 0.2
ml per well). The plates were then washed with buffer B (5
times). Thereafter 0.15 ml bradykinin Standard solution in
buffer C and 0.05 ml bradykinin enzyme conjugate were added
to the wells and incubated at 4 °C for 24 h. Then the plates
were washed with buffer B (5 times), the corresponding D-
luciferin derivative solution was added (0.2 ml) to the wells, and
the bound bradykinin conjugates were measured äs described in
Materials and Methods.
Fig. 1. Scheme of the bipluminescence enzyme immunoassays
a) competitive human urinary kallikrein assay;
b) human urinary kallikrein immuno enzymometric assay;
c) human urinary kallikrein sandwich antigen assay;
d) competitive bradykinin assay;
e) human urinary kallikrein sandwich antibody assay.
® = bradykinin, ® = human urinary kallikrein, = immunoglobulin G, L-X = luciferin derivative, L = luciferin,
Y-· = immunoglobulin G enzyme conjugate, (§)-· = bradykinin enzyme conjugate, <§)-· = human urinary kallikrein
enzyme conjugate.
For details see Methods.
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Enzyme immunoassay for titer determination
Microtiter plates were coated with antigen (10 mg/1 human
urinary kallikrein in bufler A; 0.2 mi) at 4 °C overnight. The
plates were then washed with buffer B (5 times). Thereafter 0.2
ml of difierent antiserum dilutions (10-0.001 μΐ anti-human
urinary kallikrein serum in 0.2 ml buffer C) were added and
incubated for 3 h at 37 °C. The plates were -washed -(5- times
with buffer B), 0.2 ml of goat anti-rabbit IgG enzyme conjugate
were added and incubated for 2 h at 37 °C, and the plates again
washed with buffer B' (5 times). The corresponding /Muciferin
derivative solution (0.2 ml) was added to the wells and the
bound conjugates were measured s described in Materials and
Methods.
Results and Discussion
Bradykinin, human urinary kallikrein and imrmmo-
globulin G were conjugated to carboxylic esterase,
carboxypeptidases A and B, arylsulphatase and alka-
line phosphatase, according to established methods
s described in Materials and Methods (27, 28). The
enzymatic activities of the conjugates after synthesis
were sufficiently high for their intended use (tab. 1).
Using these enzyme conjugates, a number of different
variants of immunoassays with different detection
Systems were developed for the assay of bradykinin,
human urinary kallikrein and for human urinary kal-
likrein antibody-titer determinations. The principles
of the assays are shown schematically in figure 1. The
bradykinin assay was perforrned s a cpinpetitive test
(fig. Id), whereas f r human urinary kallikrein a
competitive (fig. l a), an iiiamuno enzyinometric assay
(fig. l b), and a sandwich antigen ass ^ (fig. l c) were
established. Anti human urinary kallikrein titers were
measured by sandwich a tibody assay (fig. l e). The
assays were performed s described in Materials and
Methods.
Assay Systems were optimized with respect to enzyme
immunoassay conditions (binding of antigen/ariti-
body to microtiter plates, antibody-antigen binding,
etc.) s previ usly described (29), and to optimal
detection System conditions (concentration of sub-
strates, temperatures, etc.). Luciferin liberation at
25 °C and 37 °C (fig. 2), s well s the kinetics of the
releasing reaction, was also investigated (fig. 2). At
37 °C luciferin was liberated at a higher rate. Optimal
Substrate concentrations for the detection Systems
were determined by adding increasing amounts of/)-
luciferin derivatives to the respective assay (fig. 3).
As can be seen from the data, optimal Substrate
concentrations are in the r nge of about 10 μπιοΐ/ΐ.
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Fig. 2. Kinetics of luciferin liberation from D-luciferin deriva-
tives by surface-bound goat anti-rabbit IgG enzyme
conjugates.
a) carboxylic esterase-based detection System I;
b) carboxypeptidase A-b sed detection System II;
c) carboxypeptidase B-based detection System III;
d) arylsulphatase-based deteetion System IV;
. e) alkaline phosphatase-based detection System.
Incubation temperature: * = 37 PC,* ** == 25 °C.
• i
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In figures 4 to 8 binding curves of different types of
bioluminscence enhanced enzyme immunoassays for
human urinary kallikrein, bradykinin and antibody
titers (anti-human urinary kallikrein serum) are
shown, using different detection Systems. The Stan-
dard curves were constructed by plotting the fraction
of light impulses of the blank and the samples against
the dose of antigens either in a logit-log mode (figs.
5 and 8) or in a linear-log mode (figs. 4, 6 and 7).
The sensitivity and the slope of the curves vary,
depending on the detection system and the type of
enzyme.immunoassay. The sensitivities of the biolu-
minescence enhanced enzyme immunoassays were de-
fined according to the method described by Kaiser
(30). The lowest concentration of human urinary
kallikrein that produces a response greater than that
caused in the absence of human urinary kallikrein
was l fg per well in the immuno enzymometric assay
(fig. 7), corresponding to 5 pg/1. For bradykinin the
lowest detectable concentration was l fg per well,
corresponding to 5 pg/1 (fig. 4). The mass of antibod-
ies necessary for 50% binding in the assay was 200
fg per well, corresponding to l ng/1 specific anti-
human urinary kallikrein immunoglobulin G.
The determination of precision (intra- and inter- ssay
coefficient of Variation), specificity and recovery of
the assays led to the same results s previously pub-
lished for enzyme immunoassays with peroxidase s
label (26, 29). The relative intra-assay coefficient of
Variation (N between 15 and 25 for each assay; meas-
ured on different days) ranged from 2 to 6% for all
assays and detection Systems. The intra-assay coeffi-
cient of Variation was calculated for all Standard
curve concentrations (e. g. fig. 4; r nge 10~15 to 10"12
g/tube for o). The inter-assay coefficient of Variation
of identical samples (N between 8 and 22) and detec-
tion Systems containing all Standard curve concentra-
tions (e. g. fig. 6; concentrations used for o: 10"I2,
10-", 10-10, 10-9, 10-8 g/tube) was 4-12%.
The sensitive bioluminescence enhanced enzyme im-
munoassay developed for peptides (bradykinin), pro-
teins (human urinary kallikrein) and antibody titer
determinations should be especially suitable for stud-
ies in which highly sensitive methods are needed, e. g.
for detection of monoclonal antibody synthesis in
cell cultures, demonstration of in vitro translation
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Fig. 3. Evaluation of the optimal Substrate concentration in
the detection Systems (25 °C).
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products, etc. The high sensitivity of the biolumines-
cence enhanced enzyme immunoassay (l pg/1; in gen-
eral radio and enzyme immunoassays reach a sensitiv-
ity of 10 to 100 ng/1; (24)) was demonstrated by
0.99
10' ΙΟ'" 10'9
Bradykinin C g / t u b e ]
10- 10-'
Fig. 4. Dose response curves of bradykinin in the competitive
bradykinin bioluminescence enzyme immunoassay.
Δ, carboxylic esterase-based detection System I;
o, carboxypeptidase A-based detection System II;
a, carboxypeptidase B-based detection System III;
D, Arylsulpha.tase-based detection System IV;
o, alkaline phosphatase-based detection System V.
For details of the assay procedures see Methods.
employing various bioluminescence detection Systems
for different types of enzyme immunoassay. Depend-
ing on the enzyme conjugates and Substrates used,
turnover rates of enzymes ranged from a kcat value
of 11 s"1 (carboxylic esterase (9)) up to 1010 s"1
(alkaline phosphatase (9)). In figure 4, dose response
curves obtained for detection System fl to V in the
competitive bradykinin bioluminescence enzyme im-
munoassay are shown. As cati be seen, alkaline phos-
phatase conjugates gave a response curve with the
lowest detection limit. Titer detenninati ns (flg. 5)
and the different types of human urinary kallikrein
immunoassays (figs. 7, 8) showed simil f good results.
Alkaline phosphatase conjugates gave the best re^
sponses with the lowest limits of detection when com-
pared with the other detection Systems.
The bioluminescence enhanced enzyme irnmunoas-
says described are useful for determination of anti-
gens in a very low concentfation r nge (down to
10~15 mol/1 or 0.2 · lO^19 mol/test). Conjugates with
alkaline phosphatase are especially useful for work
requiring highest sensitivity. The assay procedure is
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Fig. 5. Binding curves of rabbit anti-human urinary kaUikrein
IgG in the human urinary kallikrein Sandwich antibody
assay.
a) carboxylic esterase-based detection System I;
b) carboxypeptidase A-based detection System II;
c) carboxypeptidase B-based detection System III;
d) arylsulphatase-based detection System IV;
„ e) alkaline phosphatase-based detection System V.
For assay conditions see Methods. ·
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simple to perform, and the Substrates are stable at
— 20 °C in the dark for more than one year. Substrate
Solutions can also be stored at — 30 °C for some
weeks.
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For assay conditions see Methode.
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Fig. 7. Binding curve of human urinary kallikrein in the im-
muno enzymetric human urinary kallikrein assay.
o, alkaline phosphatase-based detection System V.
For details see Methods.
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